http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Mar 2026 16:08:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+Zedelmayer+Christine/26132098.html si-local-file:///var/storage/secattach/20260309/26132098.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+Zedelmayer+Christine/26132098.html Mon, 09 Mar 2026 16:08:00 -0400 EQ O.38485782 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+Zedelmayer+Christine/26132098.html si-local-file:///var/storage/secattach/20260309/26132098.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+Zedelmayer+Christine/26132098.html Mon, 09 Mar 2026 16:08:00 -0400 EQ O.38485782 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Equillium%2C+Inc.+++++++++++For%3A+Feb+19++Filed+by%3A+Zedelmayer+Christine/26100697.html si-local-file:///var/storage/secattach/20260303/26100697.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Equillium%2C+Inc.+++++++++++For%3A+Feb+19++Filed+by%3A+Zedelmayer+Christine/26100697.html Tue, 03 Mar 2026 15:22:00 -0400 EQ O.38485782 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Equillium%2C+Inc.+++++++++++For%3A+Feb+19++Filed+by%3A+Zedelmayer+Christine/26100697.html si-local-file:///var/storage/secattach/20260303/26100697.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Equillium%2C+Inc.+++++++++++For%3A+Feb+19++Filed+by%3A+Zedelmayer+Christine/26100697.html Tue, 03 Mar 2026 15:22:00 -0400 EQ O.38485782 http://www.streetinsider.com/Press+Releases/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html <p>LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.</p> <p>Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.</p> <p><strong>About Equillium</strong><br/>Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is http://www.streetinsider.com/Press+Releases/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html Wed, 25 Feb 2026 08:30:00 -0400 A.36817542 EQ O.25213119 O.38485782 http://www.streetinsider.com/Press+Releases/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html <p>LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.</p> <p>Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.</p> <p><strong>About Equillium</strong><br/>Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is http://www.streetinsider.com/Press+Releases/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html Wed, 25 Feb 2026 08:30:00 -0400 A.36817542 EQ O.25213119 O.38485782 http://www.streetinsider.com/Press+Releases/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html <p>LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.</p> <p>Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.</p> <p><strong>About Equillium</strong><br/>Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is http://www.streetinsider.com/Press+Releases/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html Wed, 25 Feb 2026 08:30:00 -0400 A.36817542 EQ O.25213119 O.38485782 http://www.streetinsider.com/Press+Releases/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html <p>LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.</p> <p>Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.</p> <p><strong>About Equillium</strong><br/>Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is http://www.streetinsider.com/Press+Releases/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html Wed, 25 Feb 2026 08:30:00 -0400 A.36817542 EQ O.25213119 O.38485782 http://www.streetinsider.com/Globe+Newswire/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html <p>LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.</p> <p>Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.</p> <p><strong>About Equillium</strong><br/>Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is http://www.streetinsider.com/Globe+Newswire/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html Wed, 25 Feb 2026 08:30:00 -0400 A.36817542 EQ O.25213119 O.38485782 http://www.streetinsider.com/Globe+Newswire/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html <p>LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.</p> <p>Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.</p> <p><strong>About Equillium</strong><br/>Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is http://www.streetinsider.com/Globe+Newswire/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html Wed, 25 Feb 2026 08:30:00 -0400 A.36817542 EQ O.25213119 O.38485782 http://www.streetinsider.com/Globe+Newswire/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html <p>LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.</p> <p>Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.</p> <p><strong>About Equillium</strong><br/>Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is http://www.streetinsider.com/Globe+Newswire/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html Wed, 25 Feb 2026 08:30:00 -0400 A.36817542 EQ O.25213119 O.38485782 http://www.streetinsider.com/Globe+Newswire/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html <p>LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.</p> <p>Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.</p> <p><strong>About Equillium</strong><br/>Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is http://www.streetinsider.com/Globe+Newswire/Equillium+to+Participate+in+the+Leerink+Partners+2026+Global+Healthcare+Conference/26055833.html Wed, 25 Feb 2026 08:30:00 -0400 A.36817542 EQ O.25213119 O.38485782 http://www.streetinsider.com/New+Coverage/Stifel+Starts+Equillium+%28EQ%29+at+Buy/26051466.html <p>Stifel analyst Alex Thompson initiates coverage on Equillium (NASDAQ: EQ) with a Buy rating and a price target of $5.00.</p><p>The analyst comments "We are initiating coverage of Equillium Inc. (EQ) with a Buy Rating and $5 Target Price. Our constructive thesis on EQ, despite the preclinical status of the EQ504, is based on our broader thesis that the inflammatory bowel disease (IBD) market is in need of novel modalities to expand the armamentarium and push the efficacy ceiling either as monotherapies or orthogonal mechanisms for combinations. EQ504 is a structurally-optimized arylhydrocarbon receptor (AhR) modulator with preclinical data across Ulcerative Colitis http://www.streetinsider.com/New+Coverage/Stifel+Starts+Equillium+%28EQ%29+at+Buy/26051466.html Tue, 24 Feb 2026 16:08:04 -0400 EQ http://www.streetinsider.com/Analyst+Comments/Stifel+Starts+Equillium+%28EQ%29+at+Buy/26051466.html <p>Stifel analyst Alex Thompson initiates coverage on Equillium (NASDAQ: EQ) with a Buy rating and a price target of $5.00.</p><p>The analyst comments "We are initiating coverage of Equillium Inc. (EQ) with a Buy Rating and $5 Target Price. Our constructive thesis on EQ, despite the preclinical status of the EQ504, is based on our broader thesis that the inflammatory bowel disease (IBD) market is in need of novel modalities to expand the armamentarium and push the efficacy ceiling either as monotherapies or orthogonal mechanisms for combinations. EQ504 is a structurally-optimized arylhydrocarbon receptor (AhR) modulator with preclinical data across Ulcerative Colitis http://www.streetinsider.com/Analyst+Comments/Stifel+Starts+Equillium+%28EQ%29+at+Buy/26051466.html Tue, 24 Feb 2026 16:08:04 -0400 EQ http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Equillium%2C+Inc.+++++++++++For%3A+Feb+19++Filed+by%3A+Zedelmayer+Christine/26041669.html si-local-file:///var/storage/secattach/20260223/26041669.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Equillium%2C+Inc.+++++++++++For%3A+Feb+19++Filed+by%3A+Zedelmayer+Christine/26041669.html Mon, 23 Feb 2026 12:53:00 -0400 EQ O.38485782 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Equillium%2C+Inc.+++++++++++For%3A+Feb+19++Filed+by%3A+Zedelmayer+Christine/26041669.html si-local-file:///var/storage/secattach/20260223/26041669.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Equillium%2C+Inc.+++++++++++For%3A+Feb+19++Filed+by%3A+Zedelmayer+Christine/26041669.html Mon, 23 Feb 2026 12:53:00 -0400 EQ O.38485782 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+Zedelmayer+Christine/26029542.html si-local-file:///var/storage/secattach/20260219/26029542.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+Zedelmayer+Christine/26029542.html Thu, 19 Feb 2026 16:03:00 -0400 EQ O.38485782 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+Zedelmayer+Christine/26029542.html si-local-file:///var/storage/secattach/20260219/26029542.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+Zedelmayer+Christine/26029542.html Thu, 19 Feb 2026 16:03:00 -0400 EQ O.38485782 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/25962112.html si-local-file:///var/storage/secattach/20260206/25962112.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/25962112.html Fri, 06 Feb 2026 16:32:00 -0400 EQ O.38485782 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/25962112.html si-local-file:///var/storage/secattach/20260206/25962112.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Equillium%2C+Inc.++++++++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/25962112.html Fri, 06 Feb 2026 16:32:00 -0400 EQ O.38485782 http://www.streetinsider.com/Press+Releases/Equillium+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25930708.html <p>LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>Each stock option has an exercise price http://www.streetinsider.com/Press+Releases/Equillium+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25930708.html Mon, 02 Feb 2026 16:05:00 -0400 EQ O.38485782 http://www.streetinsider.com/Press+Releases/Equillium+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25930708.html <p>LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>Each stock option has an exercise price http://www.streetinsider.com/Press+Releases/Equillium+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25930708.html Mon, 02 Feb 2026 16:05:00 -0400 EQ O.38485782 http://www.streetinsider.com/Globe+Newswire/Equillium+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25930708.html <p>LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>Each stock option has an exercise price http://www.streetinsider.com/Globe+Newswire/Equillium+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25930708.html Mon, 02 Feb 2026 16:05:00 -0400 EQ O.38485782 http://www.streetinsider.com/Globe+Newswire/Equillium+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25930708.html <p>LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>Each stock option has an exercise price http://www.streetinsider.com/Globe+Newswire/Equillium+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25930708.html Mon, 02 Feb 2026 16:05:00 -0400 EQ O.38485782 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Equillium%2C+Inc.+++++++++++For%3A+Jan+07++Filed+by%3A+Connelly+Stephen/25832210.html si-local-file:///var/storage/secattach/20260109/25832210.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Equillium%2C+Inc.+++++++++++For%3A+Jan+07++Filed+by%3A+Connelly+Stephen/25832210.html Fri, 09 Jan 2026 17:52:00 -0400 EQ O.38485782